Evidence map›Paper›PMID 41200194›Full record

Trial reportFrontiers in immunology2025

Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.

Ling Kui, Jinqun Huang, Guoyun Wang, Jiamin Zhao, Shuangshuang Wang, Xiaoxing Qin, Leifeng Liu, Jianfei Hu, Lianjia Chen, Xingchun Wang and 20 more

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Ling Kui *Dermatology Department & Medical Cosmetology Department, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, Guangdong, China.
Jinqun Huang *Shenzhen Beichen Biotech Co., Ltd., Shenzhen, Guangdong, China.
Guoyun Wang *Dermatology Department & Medical Cosmetology Department, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, Guangdong, China.
Jiamin Zhao *Shenzhen Beichen Biotech Co., Ltd., Shenzhen, Guangdong, China.
Shuangshuang WangDermatology Department & Medical Cosmetology Department, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, Guangdong, China.
Xiaoxing QinShenzhen Beichen Biotech Co., Ltd., Shenzhen, Guangdong, China.
Leifeng LiuSuzhou ReadCrystal Biotechnology Co., Ltd, Suzhou, Jiangsu, China.
Jianfei HuSuzhou ReadCrystal Biotechnology Co., Ltd, Suzhou, Jiangsu, China.
Lianjia Chen01 Life Institute, Shenzhen, Guangdong, China.
Xingchun Wang01 Life Institute, Shenzhen, Guangdong, China.
Qing LiDermatology Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Yuqian ZhaoShenzhen Beichen Biotech Co., Ltd., Shenzhen, Guangdong, China.
Yuanyue TangShenzhen Beichen Biotech Co., Ltd., Shenzhen, Guangdong, China.
Kexu XiongDermatology Department & Medical Cosmetology Department, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, Guangdong, China.
Shuxia ZhanDermatology Department & Medical Cosmetology Department, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, Guangdong, China.
Honghua DingDermatology Department & Medical Cosmetology Department, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, Guangdong, China.
JunLing WangDermatology Department & Medical Cosmetology Department, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, Guangdong, China.
Hua CaiDermatology Department & Medical Cosmetology Department, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, Guangdong, China.
Qing ZhangDermatology Department & Medical Cosmetology Department, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, Guangdong, China.
Xiaoyan ZiDermatology Department & Medical Cosmetology Department, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, Guangdong, China.
Qiong DengThe People's Hospital of Longhua, Shenzhen, Guangdong, China.
Lian GaoThe People's Hospital of Longhua, Shenzhen, Guangdong, China.
Xuan WangDermatology Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Chaowei ZouZhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, Guangdong, China.
Huilin YangPeking University Shenzhen Hospital, Shenzhen, Guangdong, China.
Yue XiaoDepartment of Dermatology and Venereology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Bin YangDermatology Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Bingfeng LengShenzhen Beichen Biotech Co., Ltd., Shenzhen, Guangdong, China.
Li ZhangDermatology Department & Medical Cosmetology Department, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, Guangdong, China.
Gang HuDermatology Department & Medical Cosmetology Department, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Atopic Dermatitis (AD), a chronic inflammatory skin disease characterized by pruritus, dryness, redness, edema, scratching, and lichenification, ranks as the leading cause of non-fatal skin disease burden globally. Current therapeutic strategies for AD primarily act by inhibiting inflammatory pathways, yet largely fail to address Objectives: To evaluate the safety and efficacy of endolysin gel in treating AD. Methods: An infection-driven dermatitis model with AD-like features was established. Following treatment with Staphyrase Results: Statistically significant reductions in skin lesion scores, Conclusions: Topical endolysin gel is a well-tolerated, effective, and promising agent for the treatment and proactive maintenance of mild-to-moderate AD in adults.

Indexed as

Dermatitis, AtopicEndopeptidasesAdultCytokinesFemaleHumansMaleMiddle AgedStaphylococcus aureusTreatment OutcomeYoung AdultCytokinesendolysinEndopeptidasesatopic dermatitisendolysininflammatory cytokinesphageS. aureusStaphyrase®

Identifiers

PMID41200194
PMCPMC12586070

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.